Literature DB >> 33488802

Somatically acquired mutations in primary myelofibrosis: A case report and meta-analysis.

Yongming Xia1, Qingxiao Hong2, Zhibin Gao1, Shijun Wang1, Shiwei Duan2.   

Abstract

Familial myeloproliferative disease (MPD) cases account for 7.6% of the global MPD cases. The present study reported 2 cases of primary myelofibrosis (PMF). The patients were two sisters; the older sister succumbed to the disease at the age of 37, whereas the younger sister maintained a stable disease status and gave birth to a son through in vitro fertilization. Genetic analysis of bone marrow DNA samples showed that both sisters carried a Janus kinase 2 (JAK2) V617F mutation, and the older sister also had a trisomy 8 chromosomal abnormality (47, XX, +8). A systematic literature search was also performed using PubMed, CNKI and Wanfang databases, to determine the association between JAK2 and PMF. Following comprehensive screening of the published literature, 19 studies were found to be eligible for the current meta-analysis. The results showed that JAK2 V617F was a risk factor of PMF, and no sex dimorphism was observed in JAK2 V617F mutation prevalence amongst all PMF cases. In addition, there was a lack of association between the JAK2 V617F mutation and PMF-related mortality.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  Janus kinase 2 V617F; familial; primary myelofibrosis; somatic mutation

Year:  2021        PMID: 33488802      PMCID: PMC7812576          DOI: 10.3892/etm.2021.9625

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  52 in total

1.  Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019.

Authors:  Renato Sampaio Tavares; Alexandre Nonino; Katia Borgia Barbosa Pagnano; Ana Clara Kneese Virgilio do Nascimento; Monika Conchon; Laura Maria Fogliatto; Vaneuza Araújo Moreira Funke; Israel Bendit; Nelma Cristina Diogo Clementino; Maria de Lourdes Lopes Ferrari Chauffaille; Wanderley Marques Bernardo; Fabio Pires de Souza Santos
Journal:  Hematol Transfus Cell Ther       Date:  2019-05-10

2.  Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.

Authors:  Roberto Latagliata; Nicola Polverelli; Alessia Tieghi; Giuseppe Alberto Palumbo; Massimo Breccia; Elena Sabattini; Loredana Villari; Mara Riminucci; Riccardo Valli; Lucia Catani; Giuliana Alimena; Emanuela Ottaviani; Angelo Fama; Giovanni Martinelli; Margherita Perricone; Marco Spinsanti; Michele Cavo; Nicola Vianelli; Francesca Palandri
Journal:  Hematol Oncol       Date:  2017-05-16       Impact factor: 5.271

3.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Authors:  Brady L Stein; Donna M Williams; Christine O'Keefe; Ophelia Rogers; Roxann G Ingersoll; Jerry L Spivak; Amit Verma; Jarek P Maciejewski; Michael A McDevitt; Alison R Moliterno
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

4.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

Review 5.  The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.

Authors:  Kenneth Kaushansky
Journal:  Best Pract Res Clin Haematol       Date:  2007-03       Impact factor: 3.020

Review 6.  Current treatment concepts of Philadelphia-negative MPN.

Authors:  D Wolf; J Rudzki; G Gastl
Journal:  Curr Cancer Drug Targets       Date:  2011-01       Impact factor: 3.428

7.  Progression of primary myelofibrosis to polycythemia vera: A case report.

Authors:  Yan Guo; Wenwei Xu; Lin Dong; Ning Huang; Kehong Bi
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

8.  Familial myeloproliferative syndrome.

Authors:  M Pérez-Encinas; J L Bello; S Pérez-Crespo; R De Miguel; S Tome
Journal:  Am J Hematol       Date:  1994-07       Impact factor: 10.047

Review 9.  Familial chronic myeloproliferative disorders: the state of the art.

Authors:  Elisa Rumi
Journal:  Hematol Oncol       Date:  2008-09       Impact factor: 5.271

10.  Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms.

Authors:  Min Hu; Chengbo Xu; Chao Yang; Hongli Zuo; Chengjuan Chen; Dan Zhang; Gaona Shi; Wenjie Wang; Jiangong Shi; Tiantai Zhang
Journal:  J Exp Clin Cancer Res       Date:  2019-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.